Cargando…

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer

BACKGROUND: This trial evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple–negative breast cancer (mTNBC). METHODS: Eligibility criteria were mTNBC, RECIST 1.1 measurable disease, no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Yuan, Yost, Susan E, Cui, Yujie, Ruel, Christopher, Murga, Mireya, Tang, Aileen, Martinez, Norma, Schmolze, Daniel, Waisman, James, Patel, Niki, Vora, Lalit, Tumyan, Lusine, Bozoghlanian, Mari, Stewart, Daphne, Frankel, Paul H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Breast Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322142/ https://www.ncbi.nlm.nih.gov/pubmed/37023705 http://dx.doi.org/10.1093/oncolo/oyad026

Ejemplares similares

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer
por: Lavasani, Sayeh M., et al.
Publicado: (2022)

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma
por: Burkett, Wesley C., et al.
Publicado: (2023)

Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2023)

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
por: Kataoka, Nobutaka, et al.
Publicado: (2020)

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
por: Egelston, Colt A., et al.
Publicado: (2023)

Cutaneous metastasectomy: Is there a role in breast cancer? A systematic review and overview of current treatment modalities
por: Huang, Samantha, et al.
Publicado: (2022)

Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
por: De Giglio, Andrea, et al.
Publicado: (2019)

Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
por: Kamitani, Rei, et al.
Publicado: (2022)

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]‐Fluorothymidine Positron Emission Tomography Biomarker Study
por: Wesolowski, Robert, et al.
Publicado: (2020)

Advanced atypical lung carcinoid tumour successfully treated with carboplatin, etoposide and atezolizumab: A case report
por: Yamamoto, Yoshihiro, et al.
Publicado: (2022)

Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions
por: Ruggiero, Antonio, et al.
Publicado: (2017)

Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel
por: Egawa, Takashi, et al.
Publicado: (2021)

Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
por: Tsuda, Takeshi, et al.
Publicado: (2023)

How nephrotoxic is carboplatin?
por: Hardy, J. R., et al.
Publicado: (1990)

Carboplatin binding to histidine
por: Tanley, Simon W. M., et al.
Publicado: (2014)

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2022)

Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5- fluorouracil in locally advanced nasopharyngeal carcinoma
por: Dechaphunkul, Tanadech, et al.
Publicado: (2011)

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Atezolizumab in combination with carboplatin plus nab‐paclitaxel for managing combined large‐cell neuroendocrine carcinoma: A case report
por: Tsutsumi, Rei, et al.
Publicado: (2022)

Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
por: Shiono, Ayako, et al.
Publicado: (2022)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
por: Chen, Yingkai, et al.
Publicado: (2022)

Carboplatin and renal function in children.
por: Stevens, M. C., et al.
Publicado: (1991)

Haematological toxicity of carboplatin in rats.
por: Siddik, Z. H., et al.
Publicado: (1987)

Carboplatin-Induced Hypersensitivity Reaction
por: Potolidis, Evangelos, et al.
Publicado: (2012)

Hypersensitivity to Carboplatin in Children with Malignancy
por: Ruggiero, Antonio, et al.
Publicado: (2017)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab
por: Sawatari, Kosuke, et al.
Publicado: (2022)

Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
por: Kim, Soo Han, et al.
Publicado: (2023)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Validity of Weekly Administration of Carboplatin after Carboplatin-Induced SIADH: Two Case Reports and Literature Review
por: Fujitsuka, Suguru, et al.
Publicado: (2022)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
por: Ademuyiwa, Foluso O., et al.
Publicado: (2022)

Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient
por: Huang, Zhe, et al.
Publicado: (2023)

Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
por: Gentzler, Ryan D, et al.
Publicado: (2023)

Dose-related nephrotoxicity of carboplatin in children
por: English, M W, et al.
Publicado: (1999)

Reduction of carboplatin induced emesis by ondansetron.
por: Harvey, V. J., et al.
Publicado: (1991)

CARBOPLATIN DOSING FOR ADULT JAPANESE PATIENTS
por: ANDO, YUICHI, et al.
Publicado: (2014)

The Affinity of Carboplatin to B-Vitamins and Nucleobases
por: Szefler, Beata, et al.
Publicado: (2021)

Endoplasmic Reticulum Stress Is Involved in the Response of Human Laryngeal Carcinoma Cells to Carboplatin but Is Absent in Carboplatin-Resistant Cells
por: Brozovic, Anamaria, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k2q278ervllukf0r92dqhrgq57